• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Seres Therapeutics Inc (NQ: MCRB )

    0.5806 -0.0094 (-1.59%)
    Streaming Delayed Price Updated: 3:51 PM EST, Nov 14, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Seres Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Recap: Seres Therapeutics Q3 Earnings
    Seres Therapeutics (NASDAQ:MCRB) reported its Q3 earnings results on Wednesday, November 2, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Appoints Genomic Medicine and Microbiology Pioneer Claire M. Fraser, Ph.D., to its Board of Directors and Announces SER-155 Phase 1b Study Progress
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
    From Seres Therapeutics, Inc.
    Via Business Wire
    Charter Communications, Braze And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
    U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session. iQIYI, Inc. (NASDAQ: IQ) shares dipped 14.1% to $3.31 in... 
    Via Benzinga
    Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket
    Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio. 
    Via Benzinga
    Seres Therapeutics to Host Investor Webcast on December 8, 2022 to Discuss SER-109 Commercial Strategy
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates
    From Seres Therapeutics, Inc.
    Via Business Wire
    Why Pinterest Shares Jumped Around 14%; Here Are 69 Biggest Movers From Friday
    Gainers Quanergy Systems, Inc. (NASDAQ: QNGY) jumped 153.9% to close at $3.30 on Friday. 
    Via Benzinga
    Seres Therapeutics to Host Third Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on November 2, 2022
    From Seres Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Gainers 
    Via Benzinga
    Seres Therapeutics Announces FDA Acceptance of Biologics License Application for Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection for Priority Review
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association
    From Seres Therapeutics, Inc.
    Via Business Wire
    Seres Therapeutics to Present Clinical Results at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meeting
    From Seres Therapeutics, Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
      
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    Good morning, investor! It's time to start the day with a breakdown of the biggest pre-market stock movers for Tuesday morning! 
    Via InvestorPlace
    Ford, Evotec And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
    U.S. stock futures traded lower this morning after recording gains in the previous session. Here are some big stocks moving lower in today’s pre-market trading session. 
    Via Benzinga
    Why O2Micro International Is Trading Higher By 7%; Here Are 25 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Seres Therapeutics to Present at World Anti-Microbial Resistance Congress
    From Seres Therapeutics, Inc.
    Via Business Wire
    Why IMARA Jumped Around 75%; Here Are 54 Biggest Movers From Yesterday
    Gainers 
    Via Benzinga
    Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary
    Via Benzinga
    Why Korn Ferry Is Trading Lower By Over 8%, Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
    Gainers Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) jumped 64% to $0.1199. Allena Pharmaceuticals shares dipped over 30% on Tuesday after the company announced it has filed for bankruptcy. 
    Via Benzinga
    Why Seres Therapeutics Shares Are Popping Off Today
    Seres Therapeutics Inc (NASDAQ: MCRB) shares are trading higher by 13.24% to $6.12 Wednesday morning after the company announced it completed the rolling submission process for its BLA to the FDA for... 
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.